BMO Capital Markets set a $37.00 price objective on Pfizer, Inc. (NYSE:PFE) in a research report released on Tuesday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.
Other research analysts also recently issued research reports about the company. Jefferies Group LLC set a $35.00 price target on Pfizer and gave the company a neutral rating in a report on Wednesday, August 2nd. Zacks Investment Research upgraded Pfizer from a hold rating to a buy rating and set a $40.00 price target on the stock in a report on Tuesday, October 3rd. Berenberg Bank set a $39.00 price target on Pfizer and gave the company a neutral rating in a report on Tuesday, August 1st. Morgan Stanley reiterated a neutral rating and set a $35.00 price target (down previously from $38.00) on shares of Pfizer in a report on Monday, June 12th. Finally, Cowen and Company set a $43.00 price target on Pfizer and gave the company a buy rating in a report on Monday, August 14th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have issued a buy rating to the company’s stock. The company currently has an average rating of Hold and an average price target of $38.10.
Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.02. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The business had revenue of $12.90 billion for the quarter, compared to the consensus estimate of $13.08 billion. During the same quarter in the previous year, the company posted $0.64 earnings per share. Pfizer’s revenue for the quarter was down 1.9% compared to the same quarter last year.
ILLEGAL ACTIVITY NOTICE: This report was first posted by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://www.com-unik.info/2017/10/13/bmo-capital-markets-analysts-give-pfizer-inc-pfe-a-37-00-price-target.html.
In other news, insider Alexander R. Mackenzie sold 15,000 shares of the stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $33.50, for a total transaction of $502,500.00. Following the completion of the transaction, the insider now directly owns 151,474 shares in the company, valued at approximately $5,074,379. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Sally Susman sold 38,230 shares of the stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the transaction, the insider now owns 145,649 shares of the company’s stock, valued at $5,097,715. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 464,521 shares of company stock valued at $15,813,961. Company insiders own 0.06% of the company’s stock.
A number of large investors have recently modified their holdings of PFE. First Command Financial Services Inc. lifted its stake in Pfizer by 3.9% in the 1st quarter. First Command Financial Services Inc. now owns 10,338 shares of the biopharmaceutical company’s stock valued at $354,000 after purchasing an additional 384 shares during the last quarter. Tompkins Financial Corp lifted its stake in Pfizer by 23.3% in the 1st quarter. Tompkins Financial Corp now owns 113,660 shares of the biopharmaceutical company’s stock valued at $3,368,000 after purchasing an additional 21,504 shares during the last quarter. Norway Savings Bank lifted its stake in Pfizer by 19.7% in the 1st quarter. Norway Savings Bank now owns 14,473 shares of the biopharmaceutical company’s stock valued at $495,000 after purchasing an additional 2,385 shares during the last quarter. Iowa State Bank lifted its stake in Pfizer by 4.9% in the 1st quarter. Iowa State Bank now owns 133,414 shares of the biopharmaceutical company’s stock valued at $4,564,000 after purchasing an additional 6,275 shares during the last quarter. Finally, Cribstone Capital Management LLC lifted its stake in Pfizer by 55.6% in the 1st quarter. Cribstone Capital Management LLC now owns 27,477 shares of the biopharmaceutical company’s stock valued at $937,000 after purchasing an additional 9,823 shares during the last quarter. Institutional investors and hedge funds own 68.99% of the company’s stock.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
What are top analysts saying about Pfizer Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pfizer Inc. and related companies.